Zura Bio terminates prior Stone Peach/BAFFX17 agreements, issues 8.66M shares to Athanor Capital

Zura Bio Ltd

Terminated Letter Agreements with Stone Peach and BAFFX17; entered new Athanor Agreement on Dec 29, 2025.
Issued 8,657,402 Class A ordinary shares to Athanor; $7.325M upfront fee and $25M milestone payment on change of control or first regulatory approval.
Athanor receives piggyback registration rights and 2% net sales royalty on tibulizumab (ZB-106) from the Lilly license.
Audit Subcommittee review completed; no financial statement impact or employee misconduct found.
New terms deemed more commercially advantageous; prior agreements voided with broad releases.

item 1.01 item 1.02 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Zura Bio Ltd issued 8,657,402 Class A ordinary shares of common stock to Athanor Capital.

Security: common stock
Shares: 8,657,402 Class A ordinary shares
Purchaser: Athanor Capital

Exact text from the filing

the Company agreed to issue to Athanor 8,657,402 Class A ordinary shares, of par value US$0.0001 each, of the Company (the "Athanor Shares")

View on SEC.gov

25 equity issuances filed in the last 30 days. Browse all equity issuances →

Zura Bio Ltd filing history →

Source: SEC EDGAR

accession 0001104659-26-000209

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.